Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Salgaller

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1L Rivoltini, Y Kawakami, K Sakaguchi, et al.
The Prostate|April 30, 1999
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatmentG P Murphy, B A Tjoa, S J Simmons, et al.
The Prostate|May 6, 1998
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)M L Salgaller, P A Lodge, J G McLean, et al.
The Canadian Journal of Urology|June 1, 1997
Cancer immunotherapy for prostate cancerB. A. Tjoa, S. J. Erickson, V. A. Bowes, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesionsF M Marincola, Y M Hijazi, P Fetsch, et al.
The Prostate|July 3, 1998
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptidesB A Tjoa, S J Simmons, V A Bowes, et al.
The Prostate|February 11, 1999
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseG P Murphy, B A Tjoa, S J Simmons, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1L Rivoltini, Y Kawakami, K Sakaguchi, et al.
The Prostate|April 30, 1999
Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatmentG P Murphy, B A Tjoa, S J Simmons, et al.
The Prostate|May 6, 1998
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)M L Salgaller, P A Lodge, J G McLean, et al.
The Canadian Journal of Urology|June 1, 1997
Cancer immunotherapy for prostate cancerB. A. Tjoa, S. J. Erickson, V. A. Bowes, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1996
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesionsF M Marincola, Y M Hijazi, P Fetsch, et al.
The Prostate|July 3, 1998
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptidesB A Tjoa, S J Simmons, V A Bowes, et al.
The Prostate|February 11, 1999
Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseG P Murphy, B A Tjoa, S J Simmons, et al.
Pageof 4